Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Challenges and considerations for development of therapeutic proteins in pediatric patients

(2015) Yi Zhang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Peptides, mAbs, bispecifics, oh my! clinical pharmacology challenges in the development of biologics

(2015) Joan Korth-Bradley   JOURNAL OF CLINICAL PHARMACOLOGY

Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies

(2015) Diane R. Mould et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience

(2015) David Berman et al.   PHARMACOLOGY & THERAPEUTICS

Immune checkpoint modulation: Rational design of combination strategies

(2015) Dmitriy Zamarin et al.   PHARMACOLOGY & THERAPEUTICS

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

(2014) Michael A Postow et al.   Journal of Translational Medicine

Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer

(2014) Raju R Raval et al.   Journal for ImmunoTherapy of Cancer

Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies

(2013) Zinnia P. Parra-Guillen et al.   AAPS Journal

Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity

(2013) Alan G. Ramsay   BRITISH JOURNAL OF HAEMATOLOGY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions

(2013) Andrew T. Chow et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Drug development: Releasing the brakes

(2013) Karen Weintraub   NATURE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines

(2013) A Q Butt et al.   ONCOGENE

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial

(2013) Paul F. Schellhammer et al.   UROLOGY

Clinical pharmacology considerations in biologics development

(2012) Liang Zhao et al.   ACTA PHARMACOLOGICA SINICA

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

A Guide to Rational Dosing of Monoclonal Antibodies

(2012) Shuang Bai et al.   CLINICAL PHARMACOKINETICS

T-follicular helper cells survive as long-term memory cells

(2012) Jan P. Weber et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Mathematical Modeling in Immunotherapy of Cancer: Personalizing Clinical Trials

(2012) Zvia Agur et al.   MOLECULAR THERAPY

Tumor Immunotherapy Directed at PD-1

(2012) Antoni Ribas   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Advances in the development of cancer immunotherapies

(2012) Jianjun Gao et al.   TRENDS IN IMMUNOLOGY

Targeting PD-1/PD-L1 interactions for cancer immunotherapy

(2012) Laurence Zitvogel et al.   OncoImmunology

Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma

(2011) Gregory K. Pennock et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Cancer immunotherapy – revisited

(2011) W. Joost Lesterhuis et al.   NATURE REVIEWS DRUG DISCOVERY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models

(2010) Raluca Eftimie et al.   BULLETIN OF MATHEMATICAL BIOLOGY

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Enhancing immune responses to tumor-associated antigens

(2010) Jack P. Higgins et al.   CANCER BIOLOGY & THERAPY

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

Therapeutic Protein–Drug Interactions and Implications for Drug Development

(2010) S-M Huang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

CD28 and CTLA-4 coreceptor expression and signal transduction

(2009) Christopher E. Rudd et al.   IMMUNOLOGICAL REVIEWS

On immunotherapies and cancer vaccination protocols: A mathematical modelling approach

(2009) Badal Joshi et al.   JOURNAL OF THEORETICAL BIOLOGY

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity

(2008) Cédric Ménard et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA